期刊文献+

凝血酶生成试验在遗传性凝血因子缺陷症患者出血评估中的价值 被引量:4

Thrombin generation test in estimating the clinical bleeding of patients with inherited coagulation factor deficiencies
下载PDF
导出
摘要 目的探讨遗传性凝血因子V(FV)、X(FX)和XI(FXI)缺陷及FV和凝血因子VⅢ(FVⅢ)联合缺陷(F5F8D)患者的血浆凝血因子活性、凝血酶生成曲线各参数和临床出血症状之间的关系。方法采集遗传性FV(n=24)、FX(n=14)和FXI(n=18)缺陷及F5F8D(n=8)患者及携带者的外周血进行常规出凝血检查及自动校正凝血酶曲线法凝血酶生成试验。结果凝血酶生成曲线的各项参数与FV促凝活性(FV:C)及FX促凝活性(FX:C)存在双曲线趋势关系。FV或FX缺陷患者血浆中缺陷因子的活性只要达到正常人的3%,凝血酶生成潜力和峰值就达到正常值的一半以上。FV:C≤6.9%或FX:C≤2.2%的患者具有出血症状,活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)、延迟时间及达峰时间都有不同程度的延长。具有重度出血症状的3例患者的缺陷因子(FV或FX)活性均≤1.5%,APTT、PT、延迟时间和达峰时间都明显延长,且ETP=0。结论凝血酶生成试验的各项参数与凝血因子FV、FX活性及出血症状的发生及严重程度具有相关性,凝血酶生成试验结合APTT、PT及凝血因子活性可以作为评估遗传性凝血因子缺陷症患者出血倾向的有效手段。 Objective We investigated the relation between clotting factor activity,the parameters of the thrombin generation curve(the thrombogram) and the severity of clinically observed bleeding in patients with inherited deficiency of factor V(FV),factor X(FX) and factor XI(FXI),and combined deficiency of coagulation factor V and factor VⅢ(F5F8D).Methods Venous blood samples were collected from the patients and carriers with inherited deficiency of FV(n=24),FX(n=14) and FXI(n=18) and F5F8D(n=8),and routine coagulation tests and calibrated automated thrombin generation measurement were conducted.Results The parameters of thrombin generation test varied hyperbolically with the coagulation activity of FV and FX,respectively.Endogenous thrombin potential(ETP) and peak height obtained more than half normal ETP and peak height respectively,in FV deficient patients with FV:C≥3% or FX deficient patients with FX:C≥3%.The patients with FV:C≤6.9% or FX:C≤2.2% had prolonged activated partial thromboplastin time(APTT),prothrombin time(PT),lag time and time to peak,and had bleeding symptoms.In all the 3 patients with severe bleeding symptoms,the activity of deficient factor was less than 1.5%,the ETP approached to zero,and APTT,PT,lag time and time to peak all lengthened.Conclusion The properties of the thrombogram were correlated with the levels of clotting factors and the occurrence and severity of bleeding symptoms in patients with inherited deficiencies of FV or FX.The thrombin generation measurement,combined with APTT and PT,can be used as an indicator of the bleeding tendency in rare inherited deficiencies of coagulation factors.
出处 《中国实验诊断学》 北大核心 2011年第3期503-507,共5页 Chinese Journal of Laboratory Diagnosis
关键词 凝血酶生成 凝血因子V缺陷 凝血因子X缺陷 出血 ETP Thrombin generation Factor V deficiency Factor X deficiency hemorrage ETP
  • 相关文献

参考文献10

  • 1Pey~andi F, Mannucci PM. Rare coagulation disorders [J]. Thrcmb Haemost, 1999,82 : 1207.
  • 2王学锋,王鸿利.血栓与止血的检测及应用[M].上海:上海世界图书出版公司,7.005:117.
  • 3Hemker HC, Giesen P, M Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma [ J ]. Pathophysiol Haemost Thromb, 2003,33 : 4.
  • 4Hemker HC, B6guin S. Phenotyping the clotting system [ J]. Thromb Haemost, 2000,84: 747.
  • 5Xi M, Beguin S, Hemker HC. The relative importance of the factors II, VII, IX and X for the prothrombinase activity in plasma of orally anticoagulated patients [ J ]. Thromb Haemost, 1989,62 : 788.
  • 6Duchenfin J, Pan-Petesch B, Arnaud B, et al. Influence of coagulation fac- tors and tissue factor concentration on the thrombin generation test in plas- ma[J].lrom Haemost, 2008,99 : 767.
  • 7陈华云,杨芳,许冠群,陆晔玲,张利伟,戴菁,丁秋兰,奚晓东,王学锋,王鸿利.凝血酶生成试验在血友病患者中的应用[J].诊断学理论与实践,2008,7(5):503-506. 被引量:2
  • 8Al Dieri R, Peyvandi F, Santagostino E,et al.The thrombogram in rare in- herited coagulation disorders: its relation to clinical bleeding[J]. Ttm)mb Haemost, 2002,88 : 576.
  • 9Beguin S, Lindhout T, Hemker HC. The mode of action of heparin in plas- ma[ J ]. Thromb Haemost, 1988,60: 457.
  • 10Butenas S, van' t Veer C, Mann KG. "Nomml" thrombin generation [ J]. Blood, 1999,94:2169.

二级参考文献8

  • 1[2]Hubbard AR,Weller LJ,Bevan SA.Activation profiles of factor Ⅷ in concentrates reflect one-stage/chromogenic potency discrepancies[J].Br J Haematol,2002,117 (4):957-960.
  • 2[3]Hay CR,Brown S,Collins PW,et al.The diagnosis and management of factor Ⅷ and Ⅸ inhibitors:a guideline from the United Kingdom Haemophilia Centre Doctors Organisation[J].Br J Haematol,2006,133(6):591-605.
  • 3[4]Hemker HC,Giesen P,AIDieri R,et al.The calibrated automated thrombogram (CAT):a universal routine test for hyper-and hypocoagulability[J].Pathophysiol Haemost Thromb,2002,32(5-6):249-253.
  • 4[5]Quiroga T,Goycoolea M,Giesen PL,et aL Thrombin generation in platelet-poor plasma is normal in patients with hereditary mueocutaneous haemorrhages[J].Pathophysiol Haemost Thromb,2003,33(1):30-35.
  • 5[6]Giansily-Blaizot M,A1 Dieri R,Schved JF.Thrombin generation measurement in factor Ⅶ-depleted plasmas compared to inherited factor Ⅷ-deficient plasmas[J].Pathophysiol Haemost Thromb,2003,33(1):36-42.
  • 6[7]A1 Dieri R,Peyvandi F,Santagostino E,et al.The thrombogram in rare inherited coagulation disorders:its relation to clinical bleeding[J].Thromb Haemost,2002,88(4):576-582.
  • 7[8]Chantarangkul V,Clerici M,Bressi C,et al.Thrombin generation assessed as endogenous thrombin potential in patients with hyper-or hypo-coaulability[J].Haematologica,2003,88(5):547-554.
  • 8[9]Siagemund T,Petros S,Siegemund A,et al.Thrombin generation in severe haemophilia A and B:the endogenous thrombin potential in platelet-rich plasma[J].Thromb Haemost,2003,90(5):781-786.

共引文献2

同被引文献18

  • 1沈琦,郝杰,盛凤仙,李玲,王坚,马力.国产冻干人凝血酶原复合物质量标准的研究[J].中国生化药物杂志,2004,25(3):150-153. 被引量:5
  • 2纪均,张凌,姜虹,朱也森.凝血试验预测口腔颌面外科手术出血的价值[J].中国临床医学,2005,12(1):153-155. 被引量:2
  • 3池志芳.凝血试验在肝病中的临床应用价值[J].实用医技杂志,2006,13(11):1861-1862. 被引量:4
  • 4边婧,房进辉.有关凝血、抗凝、纤溶的常见试验的临床应用[J].科技信息,2007(26):258-258. 被引量:1
  • 5Sadeghi N, Kahn D, Sayed D, et al. Compositional differences in commercially available prothrombin complex concentrates [ J ]. Clin Appl Thromb Hemost,2014,20 ( 3 ) :256-269.
  • 6Rodgers GM. Prothmmbin complex concentrates in emergency bleeding disorders[J]. Am J Hematol,2012,87(9) :898-902.
  • 7Sorensen B, Spahn DR, Innerhofer P, et al. Clinical review : Prothrombin complex concentrates-evaluation of safety and thrombogenicity [ J ]. Crit Care,2011,15 ( 1 ) :201.
  • 8Kohler M. Thrombogenicity of prothrombin complex concentrates [ J ]. Thromb Res, 1999,95 ( 4 Suppl 1 ) : $13 -17.
  • 9Europe CO. European Pharmacopoeia 8.0 [ S 1. Strasbourg Cedex : the Directorate for the Quality of Medicines & Health Care of the Counci! of Europe, 2013,2429 -2430.
  • 10Kalina U, Bickhard H, Schuhe S. Biochemical comparison of seven commercially available prothrombin complex concentrates[ J]. Int J Clin Pract ,2008,62 (10) : 1614-1622.

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部